Methyl 2-cyano-3,11-dioxo-18 beta-olean-1,12-dien-30-oate is a peroxisome proliferator-activated receptor-gamma agonist that induces receptor-independent apoptosis in LNCaP prostate cancer cells.

Department of Veterinary Physiology and Pharmacology, Texas A&M University, 4466 TAMU, College Station, TX 77843-4466, USA.
Molecular pharmacology (Impact Factor: 4.12). 03/2008; 73(2):553-65. DOI: 10.1124/mol.107.041285
Source: PubMed

ABSTRACT Methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-diene-30-oate (beta-CDODA-Me) is a synthetic analog of the naturally occurring triterpenoid glycyrrhetinic acid, which contains a 2-cyano substituent in the A-ring. beta-CDODA-Me was a potent inhibitor of LNCaP prostate cancer cell growth (IC(50) approximately 1 muM) and activated peroxisome proliferator-activated receptor gamma (PPARgamma), whereas analogs without the cyano group were weakly cytotoxic and did not activate PPARgamma. beta-CDODA-Me induced p21 and p27, down-regulated cyclin D1 protein expression, and induced two other proapoptotic proteins, namely nonsteroidal anti-inflammatory drug-activated gene-1 and activating transcription factor-3. However, induction of these responses by beta-CDODA-Me was PPARgamma-independent and due to activation of phosphatidylinositol-3-kinase, mitogen-activated protein kinase, and jun N-terminal kinase pathways by this compound. In contrast, beta-CDODA-Me also decreased androgen receptor (AR) and prostate-specific antigen (PSA) mRNA and protein levels through kinase-independent pathways. beta-CDODA-Me repressed AR mRNA transcription, whereas decreased PSA mRNA levels were dependent on protein synthesis and were reversed by cycloheximide. Thus, potent inhibition of LNCaP cell survival by beta-CDODA-Me is due to PPARgamma-independent activation of multiple pathways that selectively activate growth-inhibitory and proapoptotic responses.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of novel drugs for prostate cancer refractory to androgen deprivation therapy has been of great interest due to the lack of effective treatment modalities that can prolong the survival of such patients. The recent introduction of docetaxel-based combination chemotherapy has been a breakthrough with a modest, but significant, survival benefit. However, the improved survival period measured in months is far from ideal considering the non-negligible adverse events associated with docetaxel. Thus, numerous preclinical and clinical studies have been conducted to explore more favorable approaches to hormone-refractory prostate cancer. The novel agents under investigation include new chemotherapeutic drugs, drugs targeting signal transduction pathways, apoptosis modulators, drugs targeting the tumor microenvironment, molecular chaperone inhibitors, and dietary ingredients. Unfortunately, none of these agents have shown superior single-agent activity relative to docetaxel-based therapy to date. Therefore, developing the most effective combination therapies of new agents and docetaxel-based chemotherapy seems to be a reasonable approach until novel agents that can overcome the drug resistance of hormone-refractory prostate cancer cells emerge. Drug Dev Res 69:431–450, 2008. © 2008 Wiley-Liss, Inc.
    Drug Development Research 12/2008; 69(7):431 - 450. · 0.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND AND PURPOSE: This study was performed to investigate the effects of 4-O-methylhonokiol (MH), a constituent of Magnolia officinalis, on human prostate cancer cell growth and its mechanism of action. EXPERIMENTAL APPROACH: Anti-cancer effects of MH were examined using human prostate cancer or normal cells. The effects were validated by in vivo Xenograft animal model. KEY RESULTS: Pull-down assay and molecular docking study suggested that MH may directly bind to PPAR-γ and elevate its activity. In consistent with these results, MH increased transcriptional activity of PPAR-γ, while decreased NF-κB activity. Growth inhibition of human prostate cancer cells was achieved by MH, which was blunted by PPAR-γ antagonist (GW9662). MH caused apoptotic cell death and it was related to G(0) -G(1) phase cell cycle arrest. We found that MH increased expression of the cell cycle regulator p21, and apoptotic proteins, whereas the compound decreased phosphorylation of Rb and anti-apoptotic proteins. Small interfering RNA against p21 or transfection of p21 with mutation on cyclin D1/Cdk4 binding site blocked MH-induced cell growth inhibition, and inhibition of NF-κB activity. With animal studies, MH inhibited tumor growth, NF-κB activity and expression of anti-apoptotic proteins, whereas increased transcriptional activity and expression of PPAR-γ, and the expression of apoptotic proteins as well as p21 in tumor tissues. CONCLUSIONS AND IMPLICATION: These results indicate that MH may suppress growth of human prostate cancer cells through activation of PPAR-γ, suppression of NF-κB as well as arrest of cell cycle. Thus, MH might be a useful tool for treatment of prostate cancer.
    British Journal of Pharmacology 10/2012; · 5.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A general method for the introduction of thiol groups at positions 1, 2, and 3 of glycyrrhetinic acid has been developed starting from a protected 2α,3α-oxido-derivative. Conversion into the corresponding 2β,3β-epithio-derivative was followed by ring-opening leading to either 2- or 3-substituted thio derivatives. Conversely, 3α-configured allylic alcohol intermediates derived from the 2,3-epoxide provided efficient access to both diastereoisomeric 3-thio derivatives as well as 1α-thio derivatives. The stereochemistry of the newly formed stereogenic centers was rigorously proven using X-ray crystallography.
    Tetrahedron 06/2010; 66(24):4390-4402. · 2.82 Impact Factor